IMMUNOGENICITY OF RECOMBINANT BCG VACCINES IN RHESUS MONKEYS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 一种有效的艾滋病毒/艾滋病疫苗必须同时激发病毒特异性中和抗体和细胞毒性T淋巴细胞(CTL)反应。边际免疫原性和预先存在的抗媒介免疫可能会限制目前正在评估的疫苗结构的有效性。因此，需要更好的载体系统来诱导抗HIV-1细胞免疫，并为中和抗体反应提供基础。减毒、非致病的牛分枝杆菌卡介苗具有使其成为潜在的HIV-1疫苗载体的吸引力。卡介苗已经被成功地用作结核病和麻风病的疫苗，并且可以很容易地被改造成稳定表达转基因。重组卡介苗(RBCG)在小鼠模型中表现出免疫原性和对各种感染源的保护作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. An effective HIV/AIDS vaccine will have to elicit both virus-specific neutralizing antibodies and cytotoxic T lymphocyte (CTL) responses. Marginal immunogenicity and pre-existing anti-vector immunity are likely to limit the effectiveness of the vaccine constructs currently being evaluated. Better vector systems will therefore be needed to induce anti-HIV-1 cellular immunity and prime for neutralizing antibody responses. The attenuated, non-pathogenic Mycobacterium bovis BCG has features that make it attractive as a potential HIV-1 vaccine vector. BCG has been successfully used as a vaccine for tuberculosis (TB) and leprosy, and can be readily engineered to stably express transgenes. Recombinant BCG vaccines (rBCG) have demonstrated immunogenicity and conferred protection against various infectious agents in murine models.